Clinical Trial Update: Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing hydroxyurea resistance in adults with polycythemia vera using PV-AIM predictors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycythemia Vera | Phase 4 | Status: TERMINATED